Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
Tóm tắt
Nivolumab with ipilimumab (the Regimen) is the first immuno-oncology combination treatment to demonstrate long-term clinical benefit for advanced melanoma patients. We evaluated the cost effectiveness of the Regimen in this population, with and without the availability of overall survival (OS) data. A partitioned survival model and a Markov state-transition model were developed to estimate the lifetime costs and benefits of the Regimen versus ipilimumab. These models were built with and without the availability of OS data, as only progression-free survival data were available from the head-to-head, phase III trial against ipilimumab at the time of the National Institute for Health and Care Excellence (NICE) submission. Patient utilities and resource use data were sourced from trial data or the literature. Incremental cost-effectiveness ratios (ICERs) and absolute costs were similar between the models with and without OS data, but the model with OS data generated more than 1 additional quality-adjusted life-year (QALY) across both treatment arms. In both models, based on list prices, the Regimen was the most cost-effective treatment. The analyses show that the Regimen is a cost-effective treatment for advanced melanoma patients in England, and methods to overcome the lack of OS can give reasonable estimates of QALYs gained and ICERs.
Tài liệu tham khảo
Rubio-Rodriguez D, De Diego Blanco S, Perez M, Rubio-Terres C. Cost-effectiveness of drug treatments for advanced melanoma: a systematic literature review. Pharmacoeconomics. 2017;35(9):879–93. https://doi.org/10.1007/s40273-017-0517-1.
Bristol-Myers Squibb Pharma EEIG. YERVOY 5 mg/ml concentrate for solution for infusion. Summary of product characteristics. Uxbridge: Bristol-Myers Squibb Pharma EEIG; 2016.
Bristol-Myers Squibb Pharma EEIG. OPDIVO 10 mg/mL concentrate for solution for infusion. Summary of product charcteristics. Uxbridge: Bristol-Myers Squibb Pharma EEIG; 2015.
Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541–3. https://doi.org/10.1200/JCO.2015.61.6870.
Sznol M, Callahan MK, Kluger H, Postow MA, Gordon R-A, Segal NH, et al. Updated survival, response and safety data in a phase 1 dose-finding study (CA209-004) of concurrent nivolumab (NIVO) and ipilimumab (IPI) in advanced melanoma. In: Society for Melanoma Research 2015 international congress; 18–21 Nov 2015; San Francisco.
Larkin J, Chiarion-Sileni V, Gonzalez R, Rutkowski P. Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067) (abstract no. CT075). In: AACR annual meeting 2017; 1–5 Apr 2017; Washington, DC.
Schadendorf D, Larkin J, Postow M, Chiarion-Sileni V, Gonzalez R, Rutkowski P, et al. Efficacy and safety outcomes in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity. In: 12th Congress of the European Association of Dermato-Oncology; 31 Aug–3 Sep 2016; Vienna.
National Institute for Health and Care Excellence. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab. Technology appraisal guidance (TA357). 2015. https://www.nice.org.uk/guidance/ta357. Accessed 16 Oct 2015.
National Institute for Health and Care Excellence. Nivolumab in combination with ipilimumab for treating advanced melanoma. Technology appraisal guidance (TA400). 2016. https://www.nice.org.uk/Guidance/TA400. Accessed 12 Feb 2018.
Larkin J, Hatswell AJ, Nathan P, Lebmeier M, Lee D. The predicted impact of ipilimumab usage on survival in previously treated advanced or metastatic melanoma in the UK. PLoS ONE. 2015;10(12):e0145524. https://doi.org/10.1371/journal.pone.0145524.
Briggs A, Baker TM, Gilloteau I, Orsini L, Wagner S, Paly V. Partitioned survival versus state transition modeling in oncology: a case study with nivolumab in advanced melanoma. Value Health. 2015;18(7):A338. https://doi.org/10.1016/j.jval.2015.09.130.
Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, et al. Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527–34. https://doi.org/10.1200/JCO.2007.12.7837.
Latimer N. National Institute for Health an Clinical Excellence (NICE) DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. 2011. http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf. Accessed 11 May 2018.
Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94. https://doi.org/10.1200/jco.2014.56.2736.
Office for National Statistics (ONS). National life tables, United Kingdom 2011–2013. 2014. http://www.ons.gov.uk/ons/rel/lifetables/national-life-tables/2011-2013/stb-uk-2011-2013.html. Accessed 4 Dec 2015.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.
Hatswell AJ, Porter J, Lee D, Hertel N, Latimer NR. The cost of costing treatments incorrectly: errors in the application of drug prices in economic evaluation due to failing to account for the distribution of patient weight. Value Health. 2016. https://doi.org/10.1016/j.jval.2016.04.013.
Department of Health. NHS reference costs 2014 to 2015. 2015. https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015. Accessed 6 Jan 2016.
Curtis L, Burns A. Unit costs of health & social care 2015. Canterbury: PSSRU; 2015. https://www.pssru.ac.uk/pub/uc/uc2015/full.pdf. Accessed 6 Jan 2016.
Bullement A, Critchlow S. An exploration of techniques for addressing uncertainty in survival estimates used within partitioned-survival models. Value Health. 2016;19(7):A378–9. https://doi.org/10.1016/j.jval.2016.09.185.
Scottish Medicines Consortium. Nivolumab 10 mg/mL concentrate for solution for infusion (Opdivo®). SMC no. (1187/16). 2016. https://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_Oct_2016_Amended_01.11.16_for_website.pdf. Accessed 13 Feb 2018.
Oriana C, Martin H, Toby P, Chris C, Ruth G, Claudius R, et al. Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence. Value Health. 2013;16(6):1081–90. https://doi.org/10.1016/j.jval.2013.07.004.
National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Process and methods (PMG9). 2013. https://www.nice.org.uk/process/pmg9/chapter/foreword. Accessed 4 Dec 2015.
Monthly Index for Medical Specialities. Database of prescription and generic drugs, clinical guidelines. 2016. https://www.mims.co.uk/. Accessed 4 Dec 2015.
Oxford Outcomes. Advanced melanoma resource use and costs in Europe: final report. Vancouver: Oxford Outcomes; 2011 (data on file).
Addicott R, Dewar S. Improving choice at end of life: a descriptive analysis of the impact and costs of the Marie Curie delivering choice programme in Lincolnshire. London: King’s Fund; 2008. https://www.kingsfund.org.uk/sites/default/files/improving-choice-end-of-life-descriptive-analysis-impact-costs-marie-curie-choice-programme-lincolnshire-rachael-addicot-steve-dewar-april-2008.pdf. Accessed 4 Dec 2015.
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. https://doi.org/10.1056/NEJMoa1412082.